Figure 5.

Characterization of cardiac fibrosis in cardiorenal HFpEF and reduced cardiac fibrosis and collagen deposition after treatment with Telmisartan. (a) Masson staining and (b) the calculated mean ± SD of percentage of cardiac fibrosis at week 16. (c) Real-time PCR and (d) western blotting of collagen I and collagen III in heart tissues at week 16 and the calculated mean ± SD of protein/β-actin ratios of collagen I and collagen III. Scale bar in (a), 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001 for SNX+Veh vs. Sham; #P < 0.05, ##P < 0.01, ###P < 0.001 for SNX+Veh vs. SNX+Tel. (A color version of this figure is available in the online journal.)